Board News and Announcements




JULY 2019 NEWSLETTER - Individuals wishing to subscribe to the quarterly NABP/NCBOP newsletter may do so here (follow link.)



TUESDAY, JULY 23, 2019

HOPE ACT AUTHORIZES CERTIFIED DIVERSION INVESTIGATORS TO OBTAIN PRESCRIPTION RECORDS.  The 2018 HOPE Act authorizes certain law enforcement officers to obtain pharmacy records directly.  This FAQ document explains those provisions of the Act, which went into effect on July 1, 2019.




*UPDATE* GENERAL ASSEMBLY PASSES, AND GOVERNOR COOPER SIGNS INTO LAW, NEW VACCINE ADMINISTRATION AUTHORITY FOR PHARMACISTS. On June 3, Governor Cooper signed into law S.L. 2019-21, which will increase pharmacists’ authority to administer vaccines. Here’s what you need to know:

1. Will pharmacists be able to administer more vaccines to patients 18 and older pursuant to protocol? Yes. This legislation adds Serogroup B meningococcal vaccines, human papillomavirus vaccine, and Hepatitis A vaccine to the list of vaccines that a pharmacist may administer to persons 18 or older pursuant to protocol.

2. Will pharmacists be able to administer flu vaccine by protocol to younger patients? Yes. This legislation authorizes pharmacists to administer flu vaccine to patients at least ten (10) years old pursuant to protocol. Pharmacists are authorized to administer flu vaccine to patients at least six (6) years old pursuant to a prescription order.

3. Is this new authority effective now? No. The legislation becomes effective on October 1, 2019.

4. What happens between now and October 1, 2019? A couple of things.

First, the North Carolina Academy of Family Physicians, the North Carolina Medical Society, the North Carolina Pediatric Society, the North Carolina Association of Community Pharmacists, the North Carolina Association of Pharmacists, and the North Carolina Retail Merchants Association have produced (as required in the statute) a new minimum standard screening questionnaire for immunizing pharmacists. You can download the revised questionnaire here.

Second, Board staff recommends that immunizing pharmacists collaborate with their supervising physicians to revise their vaccination protocols to reflect the new vaccines that may be administered and the new permissible age for flu vaccine administration.

5. I’d like to read the new legislation. Where can I get it? Right here, dear reader.




GENERAL ASSEMBLY PASSES AND GOVERNOR COOPER SIGNS INTO LAW LEGISLATION ALLOWING DONATION OF MORE DRUGS TO FREE AND CHARITABLE PHARMACIES.  Late last month, the General Assembly passed an amendment to NCGS 90-85.44, which governs the donation of drugs and devices in North Carolina.  Prior to this amendment, North Carolina law required that a donated drug or device have at least six months remaining on its expiration date at the time of donation.  As amended, the statute makes a drug eligible for donation if, among other things, the drug has not reached its expiration date at the time of donation.  Board staff has updated the FAQ on drug donation to reflect this change.  Pharmacists are encouraged to review that FAQ -- -- for a refresher on drug donation regulation. 



FRIDAY, JUNE 21, 2019

DISPENSING OF ORAL TYPHOID VACCINE.  Several pharmacists have contacted Board staff with questions about how, if at all, the immunizing pharmacist provisions of the Pharmacy Practice Act impact the dispensing of oral typhoid vaccine (marketed as Vivotif).  The short answer is that, for all practical purposes, they do not.  Recall that the immunizing pharmacist provisions of the Pharmacy Practice Act speak to whether and under what circumstances a pharmacist may administer a vaccine to a patient.  The dispensing of oral typhoid vaccine, which a patient self-administers just as any other oral medication, is not limited those provisions governing vaccine administration.  The most frequent question concerning oral typhoid vaccine is along the following lines:  “I have a prescription for oral typhoid vaccine for a 16-year-old patient.  But the immunizing pharmacist provision limit administration of vaccines other than those allowed by protocol to patients 18 or older.  May I nonetheless dispense the oral typhoid vaccine to this patient?”  Again, the answer is yes.  Limitations on vaccine administration do not prohibit the dispensing of this self-administered oral vaccine to a patient, regardless of age, pursuant to a valid prescription. 



NEW CE OPPORTUNITIES: PHARMACISTS & TECHNICIANS, Remember to check our CE page often for upcoming CE programs in your area. (LAST UPDATED JULY 11, 2019.)


TUESDAY, JUNE 18, 2019


I have fought a good fight, I have finished my course, I have kept the faith . . .  2 Timothy 4:7

Carol Smith passed away on June 15 after a long, courageous battle with cancer.  Carol spent 30 years at the Board of Pharmacy, much of that as the Director of Operations working as David Work's right-hand person to implement the many changes that transformed the Board into a nationally admired, forward-thinking regulatory agency.  Carol’s imprint on the Board is indelible.  Indeed, some might say – including David – that Carol “really” ran the Board in many of those years.  She also recruited and hired many of the Board’s staff, and set an example of loyalty, hard work, and excellence that inspired and challenged.

We were fortunate after Carol’s retirement to continue seeing her regularly at Board events both joyous and sad.   Rachel Paris, the Board’s beloved, long-time Director of Licensing, was Carol’s best friend and was with her at her passing.   Carol was, and remained, a wonderful member of our family.  We will miss her terribly. 

A service for Carol will be held this Friday, June 21, 3 p.m. at the Salem United Methodist Church in Haw River, NC.  The family requests that, in lieu of flowers, memorials be made to the Church (4924 Salem Church Road, Haw River, NC 27258), the Duke Cancer Institute (710 West Main Street, Suite 200, Durham, NC  27701), or Relay for Life of Alamance County. 





United States Pharmacopeia (USP) has published the chapter revisions for USP <795> and <797>, for non-sterile and sterile compounding.  USP also published the newly developed chapter <825> on Radiopharmaceuticals.  These chapters along with USP Chapter <800> Handling of Hazardous Drugs  will become enforceable for compounding operations on December 1, 2019.  USP has made USP Chapters <797>, <797>, <800>, and <825> available free to download at Board Staff will be posting guidance documents about the updated USP Chapters and also will be posting our updated inspection forms with the updates incorporated. 

In the meantime, USP has developed very detailed FAQs on all four chapters. 
USP <800>:
USP <825>:

With respect to USP Chapter <800> and non-compounding activities involving hazardous medications pharmacists are reminded that the Board’s position is as follows:

NC Board of Pharmacy's position with respect to USP <800> standards and their application to non-compounding activities involving hazardous medications

The NC Board of Pharmacy views compliance with USP <800> as a best practice for pharmacies who are doing non-compounding activities with hazardous medications. As pharmacists know, USP Chapter <800> standards are designed to protect pharmacists, pharmacy staff, patients, and the public from the harmful effects of exposure to hazardous medications.

As USP Chapter <800> standards for non-compounding activities become commonly followed, North Carolina law is likely to reflect that doing so is considered standard of practice.  In that case, failure to comply may be evidence of negligence.  Therefore, you are encouraged to evaluate (and to continue to re-evaluate) to what extent compliance reflects the appropriate standard of care.  Board staff will continue to make observations during inspections to help identify potential risk for handling Hazardous Medications, and will provide education on how to comply with USP Chapter  <800> standards to minimize risk to pharmacy staff, patients, and the public.  These observations regarding USP Chapter <800> compliance in non-compounding activities involving Hazardous Medications will not, by themselves, serve as a basis for disciplinary action by the Board. The Board's full position statement may be found here:
Board Staff have created helpful educational information that addresses identification of Hazardous Drugs, instructions on conducting an Assessment of Risk, and templates for non-compounding pharmacies to develop Standard Operating Procedures (SOPs) addressed in USP<800>. This informational material is for pharmacies that DO NOT compound with hazardous medications:
As a reminder Board issued a statement on September 29, 2017 statement regarding, pharmacies that perform any nonsterile or sterile compounding with Hazardous Medications must be in full compliance with USP <800> when the chapter becomes official December 1, 2019 in accordance to NCAC 46. 2801. That position statement may be found here:



FRIDAY, MAY 31, 2019

As noted here in greater detail, the next North Carolina Board of Pharmacy elections are scheduled to begin November 1, 2019. Two district seats will be up for election this year: the Central District and the Northeastern District.

Board staff will host two question-and-answer sessions in September. Anyone interested in learning more about Board service and the election process should plan to attend one of these sessions:

Please contact Jay Campbell with any questions.



MONDAY, APRIL 22, 2019

ATLAS PHARMACEUTICAL ANNOUNCES RECALL OF MISBRANDED LOTS OF COMPOUNDED METRONIDAZOLE MINI TABS FOR VETERINARY CLINICS.  Veterinary clinics are directed to this information concerning a recall of compounded veterinary products:




FDA AND NORTH CAROLINA DEPARTMENT OF AGRICULTURE EMPHASIZE THAT CBD-CONTAINING SUPPLEMENTS ARE NOT LAWFUL UNDER THE FEDERAL AND NORTH CAROLINA FOOD DRUG & COSMETIC ACTS. On December 20, 2018, FDA Commissioner Scott Gottlieb issued a statement explaining that while the Farm Bill of 2018 removed hemp from the federal Controlled Substances Act, "Congress explicitly preserved the [FDA's] authority to regulate products containing cannabis or cannabis-derived compounds under the FD&C Act."  Hence, the FDA "treat[s] products containing cannabis or cannabis-derived compounds as [it does] any other FDA-regulated products."  Importantly, FDA reminded the regulated community that it is "unlawful under the FD&C Act . . . to market CBD or THC products as, or in, dietary supplements, regardless or whether the substances are hemp derived.  This is because both CBD and THC are active ingredients in FDA-approved drugs and were the subject of substantial clinical investigations before they were marketed as . . . dietary supplements."  The full text of Commissioner Gottlieb's statement may be found here:

In late February, the North Carolina Department of Agriculture -- which directly regulates industrial hemp products in North Carolina -- began sending letters to businesses that manufacture or sell CBD-containing products emphasizing that "North Carolina has routinely adopted by reference the federal Food, Drug & Cosmetic Act and implementing regulations.  The violation of these federal laws and regulations would equally be a violation of state laws and regulations."  The Department of Agriculture's letter -- like Commissioner Gottlieb's statement -- emphasizes that "CBD is the active ingredient in the approved drug product Epidiolex" and that "[s]ince CBD is the active ingredient in the approved drug product Epidiolex, it is currently excluded from being a dietary supplement under section 210(ff)(3)(B)(i) and (ii) of the FD&C Act." 

The North Carolina Department of Agriculture further emphasized that "CBD products marketed with claims to prevent, mitigate, diagnose, treat or cure diseases" make those products "drugs under the FD&C Act."  Accordingly, "CBD in products other than the approved drug Epidiolex and which make health claims would be a new drug that cannot legally be introduced into interstate commerce."

The full text of the Department of Agriculture letter is found here:

Board staff trusts this clears up any lingering confusion concerning CBD-containing supplements.




Board Requirements on Submitting Drug Disaster & Loss Report, Incident Reports, and Drug Disposal Forms

Since August 2017, in an ongoing effort to increase efficiency and to provide the most secure platform possible, the NC Board of Pharmacy transitioned to a new online licensing/enforcement system. It grants access to printable documents, change of address, online applications and many more features.  This also includes Drug Disaster and Loss Reports, Drug Disposal Forms, and Incident Reports.

Drug Disaster & Loss Reports, Incident Reports, and Drug Disposal Forms must be submitted by pharmacist manager or designated permit personnel through the Licensure Gateway. Board staff no longer accepts faxed notifications of potential medication loss; DEA 106 forms; and Drug Disaster & Loss Reports, Incident Reports or Drug Disposal Forms submitted by fax, email, or USPS mail.

 A reminder to all pharmacist managers/pharmacists in charge on statutes and rules pertaining to these reports:

  1. Drug Disaster and Loss Reports - NCGS 90-85.25(B) states that “the pharmacist in charge of a pharmacy shall report within 10 days to the Board any disaster, accident, theft, or emergency which may affect the strength, purity, labeling of drugs and devices in the pharmacy”.
  2. Incident Reports - 21 NCAC 46.2502(l) states that “The pharmacist-manager shall report to the Board of Pharmacy information that reasonably suggests that there is a probability that a prescription drug or device dispensed from a location holding a permit has caused or contributed to the death of a patient or customer. This report shall be filed in writing on a form provided by the Board within 14 days of the owner representative or pharmacist-manager's becoming aware of the event. The pharmacist-manager shall retain all documents, labels, vials, supplies, substances and internal investigative reports relating to the event. All such items shall be made available to the Board upon request”.
  3. Drug Disposal Forms – 21 NCAC 46.3001(a) states that “All registrants under G.S. 90-85.21 shall develop and implement policies and procedures to insure that all out-dated, improperly labeled, adulterated, damaged or unwanted drugs or drug containers with worn, illegible or missing labels are destroyed or disposed of so as to render them unusable.”




FDA STEPS UP ENFORCEMENT ACTIVITIES AGAINST MAKERS OF “DIETARY SUPPLEMENTS” THAT MAKE UNSUBSTANTIATED CLAIMS REGARDING DISEASE TREATMENT AND/OR CONTAIN PRODUCTS THAT HAVE BEEN APPROVED AS DRUGS.  In recent weeks, the FDA has stated its intent to step up enforcement activities against people and entities marketing “dietary supplements” in a way that, in fact, makes those supplements adulterated and misbranded drugs.  Last week, the FDA followed through and issued a number of warning letters, including one to an outfit based in Blowing Rock, NC marketing “colloidal silver” products.  FDA’s recent actions are a reminder to pharmacists of their legal and professional responsibilities to sell and counsel on dietary supplements in a way strictly compliant with federal regulation and with the patient’s health and well-being.  More information here:





FDA STATEMENT CONCERNING CBD PRODUCTS AFTER PASSAGE OF THE FARM BILL.  A number of pharmacists have inquired about the status of CBD-containing products after passage of the Farm Bill late last month.  On December 20, 2018, FDA Commissioner Scott Gottlieb issued a statement about what the Farm Bill changed – and, as importantly, did not change – when it comes to CBD products:




Pharmacists continue to call Board staff with understandable confusion on whether and how “on file” controlled substance prescriptions that were never filled may be transferred. To recap:

In April 2017, word began swirling that DEA viewed transfers of “on file” controlled substances as not allowed.  On July 7, 2017, Loren Miller, Associate Section Chief, Liaison and Policy Section, Diversion Control Division, Drug Enforcement Administration sent an email to Carmen Catizone, Executive Director of the National Association of Boards of Pharmacy, setting forth DEA’s view on the matter.

In that email (found here --, Mr. Miller states the view that 21 CFR 1306.25 allows a pharmacy, “once it has filled an original prescription for a controlled substance in Schedule III-V,” to “transfer the original prescription information to another DEA registered pharmacy for the purposes of allowing that second pharmacy to then dispense any remaining valid refills . . . .”  Mr. Miller further stated that “an allowance currently does not exist for the forwarding of an unfilled prescription from one DEA registered retail pharmacy so that it may be filled at another DEA registered pharmacy.”

Mr. Miller then stated that, based on “the preamble” of an “interim final rule,” it is DEA’s “policy” that an electronic prescription for a controlled substance of any schedule may be “forwarded from one DEA registered retail pharmacy to another DEA registered retail pharmacy” even if that prescription had not been filled.

To say that DEA’s positions in this matter create a mess is a gross understatement.  First, while Mr. Miller’s reading of 21 CFR 1306.25 is textually plausible, it represents a departure from decades of standard pharmacy practice and there has been no suggestion from DEA or anyone else that the standard practice of transferring “on file” but unfilled (as opposed to once-filled) controlled substance prescriptions has caused or materially contributed to controlled substance abuse or misuse.  Second, neither Mr. Miller’s email nor any language in the preamble he references contains so much as a hint as to what an appropriate mechanism for “forwarding” (and documenting the forwarding of) an unfilled electronic controlled substance prescription would be.  Third, Mr. Miller’s email does not explain why “forwarding” an unfilled electronic controlled substance prescription is substantively different than transferring an unfilled controlled substance prescription, whether electronic, verbal, or written.  Fourth, DEA’s position creates not only an incentive, but a practical necessity, for patients  seeking to change their pharmacy of choice to obtain duplicate controlled substance prescriptions from their caregiver.  Interpretations and policies that guarantee duplicate prescriptions for controlled substances in multiple pharmacies hardly seems consistent with the Controlled Substance Act’s purpose to create a controlled, closed distribution system and minimize controlled substance abuse and misuse.

All that said, however, DEA has shown no inclination to reconsider or clarify these positions.  Where does that leave us?

(1)  Though “forwarding” of unfilled electronic controlled substance prescriptions is available by “policy,” the lack of any guidance from DEA on how a “forwarding” should occur and be documented means that most pharmacies and pharmacists are reluctant to entertain the practice.  And who can blame them?

(2)  For unfilled verbal prescriptions for a Schedule III-V controlled substances, DEA’s position means that there is no mechanism for moving them from one pharmacy to another.

(3)  For unfilled paper prescriptions for a Schedule III-V controlled substances, a pharmacy could return the original to the patient to physically carry to another pharmacy.  Board staff understand completely the practical problems of this approach.

Some pharmacists have inquired why Board staff, the Board, or the North Carolina legislature have taken this position.  As the above makes clear, none of the three are to blame.  The present state of affairs is attributable solely, and entirely, to the DEA.  Board staff will, of course, update pharmacists if the DEA sees reason and backs away from these positions.  Until then, send your cards, letters, and calls to the DEA. 





Beginning February 8, 2018, the Board of Pharmacy opened an opioid public service announcement campaign on Wilmington and Greenville-area television stations and on social media platforms. The advertisements feature Joe Adams, a pharmacist and past president of the National Association of Boards of Pharmacy, sharing his deeply personal story of losing his son to an opioid overdose in 2014. These ads emphasize the important of obtaining help and the critical role pharmacists can play.

The ads come in 30-second, 60-second, and 6-minute versions, and are available for download here. Board members and staff welcome and encourage pharmacists using these ads to educate their patients and communities about proper medication use and the dangers of opioid abuse.

The Board thanks Third Wheel Media of Chapel Hill and the National Association of Boards of Pharmacy (NABP) for their tremendous efforts on this issue. Pharmacists will note that texting “abuse” to 555888, as instructed in the ads, will result in a reply text providing a link to an NABP-created and hosted page containing resources for pharmacists to share with patients and their communities. That page may be accessed directly here:

These ads are the first phase of a multi-media campaign. Board staff will continue to keep pharmacists updated as the campaign progresses.

Please contact Board staff at 919.246.1050 with questions.



The North Carolina Board of Pharmacy's monthly meetings are live-streamed via YouTube. Follow the link below to subscribe to the Board's YouTube channel. Meeting dates found here.



Health Advisories (last updated October 10, 2018) - Check here regularly for the latest alerts and recall notices.



Medicare/Medicaid (last updated January 3, 2018) - Check here regularly for the latest updates regarding Medicare/Medicaid.


Looking for a news item that is no longer here? Try our search page or send an email to Kristin Moore.


The North Carolina Board of Pharmacy's mission is to protect the public health, safety and welfare in pharmaceutical matters. The Board sets standards for academic and practical experience programs prior to licensure, issues permits to operate pharmacies and DME facilities, and annually renews licenses, permits and registrations.

For more information, please see About the NCBOP.

Copyright © 2006 North Carolina Board of Pharmacy
site design IV Design